**Table S1**: Socio-demographic, comorbidity and clinical-related independent variables collected from a cohort of non-infectious uveitis patients.

|  |  |  |  |
| --- | --- | --- | --- |
| Variable name | Category | Type | Values |
| Gender† | Socio-demographic | Dichotomic | Man, Woman |
| Age at inclusion† | Socio-demographic | Continuous | - |
| Country of origin† | Socio-demographic | Dichotomic | Spain, other |
| Place of referral to the HCSC-UC† | Socio-demographic | Categorical | Emergency room, primary care physician, other ophthalmologist, other specialties |
| Educational level† | Socio-demographic | Categorical | None, primary, secondary, superior education |
| Marital status† | Socio-demographic | Categorical | Single, married, divorced/separated, widow |
| Employment status† | Socio-demographic |  | Student, active worker, housewife, retired, unemployed |
| Temporary or permanent disability† | Socio-demographic | Dichotomic | Yes, no |
| Charlson comorbidity index† | Comorbidity | Continuous | - |
| Presence of systemic inflammatory diseases† | Comorbidity | Dichotomic | Yes, no |
| Smoking habita† | Comorbidity | Categorical | Never smoker, previous smoker, current smoker |
| Age at first visit in the HCSC-UC† | Clinical-related | Continuous | - |
| Age at uveitis symptoms onset† | Clinical-related | Continuous | - |
| Year of disease onset† | Clinical-related | Continuous | - |
| Location of inflammation† | Clinical-related | Categorical | Anterior, intermediate, posterior, panuveitis |
| Duration of diseaseb† | Clinical-related | Continuous | - |
| Laterality† | Clinical-related | Dichotomic | Unilateral, bilateral |
| Course† | Clinical-related | Categorical | Acute non relapsing, acute relapsing, chronic32 |
| Uveitis diagnosis | Clinical-related | Categorical | Juvenile idiopathic arthritis, Behçet disease, ophthalmologic chorioretinitis, inflammatory bowel disease, multiple sclerosis, primary panuveitis, sarcoidosis, spondyloarthritis, ophthalmologic anterior uveitis, B27 positive anterior uveitis, primary intermediate uveitis, Vogt-Koyanagi-Harada syndrome, primary vascular retinitis |
| Current best corrected visual acuity of the better seeing eyec† | Clinical-related | Continuous | - |
| Current inflammatory activityd† | Clinical-related | Dichotomic | Active, inactive |
| Ocular comorbiditiese† | Clinical-related | Dichotomic | Present, absent |
| Current treatmentf† | Clinical-related | Categorical | None, only local corticosteroids, systemic corticosteroids, non-biologic immunosuppressant drugs, biologic immunosuppressant drugs |

aSmoking habit was defined as never smoker, i.e. less than 100 smoked cigarettes, previous smoker, i.e. those that quitted smoking at least 1 year before the inclusion in the study, and current smoker.

bDuration of disease was measure in years.

cBest corrected visual acuity of the better seeing eye was assessed using the Snellen chart.

dCurrent inflammatory activity was define as the present of at least one of the following: 0.5+ or more of cells in anterior chamber, presence of active or fresh keratic precipitates, 0.5+ or more of vitreous haze, presence of snowbanks, snowballs, active chorioretinitis, papilitis, retinal vasculitis, cystoid macular edema, and/or exudative retinal detachment.

eOcular comorbidities included the presence of epiretinal membrane, subretinal neovascularization, macular atrophy, glaucoma, cataracts, and/or previous ocular surgery.

fCurrent treatment was defined as none, only local corticosteroids, systemic corticosteroids (patients on both local and systemic corticosteroid treatments were categorized as systemic corticosteroids treatment), non-biologic immunosuppressant drugs (patients on local and/or systemic corticosteroids treatments, and non-biologic immunosuppressant drugs treatment were categorized as non-biologic immunosuppressant drugs treatment), and biologic immunosuppressant drugs (patients on local and/or systemic corticosteroids treatments and/or non-biologic immunosuppressant drugs treatment, and biologic immunosuppressant drugs were categorized as biologic immunosuppressant drugs treatment).

† Variables considered for the calculation of the Bonferroni adjustment.